Format

Send to

Choose Destination
See comment in PubMed Commons below
Lasers Surg Med. 2003;32(2):101-10.

Topical rose bengal: pre-clinical evaluation of pharmacokinetics and safety.

Author information

1
Provectus Pharmaceuticals, Inc., Knoxville, Tennessee 37931, USA. wachter@provectuscorp.com

Abstract

BACKGROUND AND OBJECTIVES:

Rose bengal (RB) is a potent photosensitizer that has largely been overlooked as a potential photodynamic therapy (PDT) agent. In this study, the feasibility of topical delivery of RB to the epidermis has been evaluated.

STUDY DESIGN/MATERIALS AND METHODS:

Topical formulations of RB were assessed on murine and rabbit skin for pharmacokinetic properties, cutaneous toxicity, and photosensitization.

RESULTS:

Hydrophilic formulations (<or=1% RB) exhibited rapid, selective, uniform delivery to the epidermis, with no significant acute cutaneous toxicity in normal skin. Illumination (532 nm) elicited no acute phototoxicity for light intensities <or=100 mW/cm(2) at a light dose of 100 J/cm(2); use of higher intensities resulted in superficial thermal damage. Repeat treatment of rabbit skin (weekly for four weeks) elicited minor phototoxicity only at the highest concentration (1% RB).

CONCLUSIONS:

These results indicate that RB is safe for PDT treatment of skin disorders, exhibiting negligible effects in normal skin.

PMID:
12561042
DOI:
10.1002/lsm.10138
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center